TTRX

Turn Therapeutics Inc. (TTRX) SWOT Analysis Analysis (2026)

Invetso Score: 2.5/10 — Weak · Last Updated: 2026-08-01

Strengths

Negative ROIC indicates capital deployment is destroying value versus peers, implying weaker long-term positioning unless returns improve materially.

The extremely negative cash conversion cycle suggests unusually favorable working-capital mechanics versus peers, supporting liquidity and funding flexibility.

Limited near-term leverage pressure relative to equity can preserve operating flexibility versus more indebted peers, despite the company’s overall weak profitability profile.

Weaknesses

Negative ROIC versus profitable peers signals structurally poor capital efficiency, which directly weakens margin durability and reinvestment capacity.

Debt-to-equity is elevated versus peers, increasing financial risk and constraining strategic flexibility when operating performance remains weak.

Net debt to EBITDA near 1.0 still matters because weak earnings quality makes even moderate leverage more burdensome than for stronger peers.

Current and quick ratios around 1.19 indicate only modest liquidity headroom versus better-capitalized peers, limiting resilience in a downturn.

Opportunities

Improving working-capital discipline could convert the unusually negative cash conversion cycle into a durable peer advantage in liquidity and funding efficiency.

If management lifts invested-capital returns above peers, the company could narrow its structural valuation and reinvestment gap over the next two to five years.

Balance-sheet repair could reduce the penalty from high leverage versus peers, improving strategic optionality and lowering financing drag.

Threats

Persistent negative ROIC threatens competitive positioning because peers with positive returns can compound capital faster and widen the performance gap.

High leverage versus peers increases vulnerability to refinancing stress and earnings volatility, especially if operating recovery remains delayed.

Weak liquidity relative to stronger peers raises the risk that adverse working-capital swings could force dilutive financing or constrained investment.

If capital efficiency does not improve, peers with superior profitability and balance-sheet strength can outcompete TTRX on pricing, growth, and resilience.

Overall Score

TTRX screens as structurally weak versus peers because negative capital returns and elevated leverage outweigh its limited working-capital flexibility.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Turn Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →